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Liver ﬁbrosis is part of the structural and functional alterations in
most chronic liver diseases. It is one of the main prognostic fac-
tors as the amount of ﬁbrosis is correlated with the risk of devel-
oping cirrhosis and liver-related complications in viral and non-
viral chronic liver diseases [1,2]. Liver biopsy has traditionally
been considered the reference method for evaluation of tissue
damage such as hepatic ﬁbrosis in patients with chronic liver dis-
ease. Pathologists have proposed robust scoring system for stag-
ing liver ﬁbrosis such as the semi-quantitative METAVIR score
[3,4]. In addition computer-aided morphometric measurement
of collagen proportional area, a partly automated technique, pro-
vides an accurate and linear evaluation of the amount of ﬁbrosis
[5]. Liver biopsy gives a snapshot and not an insight into the
dynamic changes during the process of ﬁbrogenesis (progression,
static or regression). However, immunohistochemical evaluation
of cellular markers such as smooth muscle actin expression for
hepatic stellate cell activation, cytokeratin 7 for labeling ductular
proliferation or CD34 for visualization of sinusoidal endothelial
capillarization or the use of two-photon and second harmonic
generation ﬂuorescence microscopy techniques for spatial assess-
ment of ﬁbrillar collagen, can provide additional ‘‘functional’’
information [6,7]. All these approaches are valid provided that
the biopsy is of sufﬁcient size to represent the whole liver [4,8].
Indeed, liver biopsy provides only a very small part of the whole
organ and there is a risk that this part might not be representa-
tive for the amount of hepatic ﬁbrosis in the whole liver due to
heterogeneity in its distribution [9]. Extensive literature has
shown that increasing the length of liver biopsy decreases the
risk of sampling error. Except for cirrhosis, for which micro-frag-
ments may be sufﬁcient, a 25 mm long biopsy is considered an
optimal specimen for accurate evaluation, though 15 mm is con-
sidered sufﬁcient in most studies [10]. Not only the length but
also the caliber of the biopsy needle is important in order to
obtain a piece of liver of adequate size for histological evaluation,
with a 16 gauge needle being considered as the most appropriate
[11] to use for percutaneous liver biopsy. Interobserver variationJournal of Hepatology 20
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Open access under CC BY-NC-ND license.is another potential limitation of liver biopsy which is related to
the discordance between pathologists in biopsy interpretation,
although it seems to be less pronounced when biopsy assessment
is done by specialized liver pathologists [12]. Beside technical
problems, liver biopsy remains a costly and invasive procedure
that requires physicians and pathologists to be sufﬁciently
trained in order to obtain adequate and representative results –
this again limits the use of liver biopsy for mass screening. Last
but not least, liver biopsy is an invasive procedure, carrying a risk
of rare but potentially life-threatening complications [13,14].
These limitations have led to the development of non-invasive
methods for assessment of liver ﬁbrosis. Although some of these
methods are now commonly used in patients for ﬁrst line
assessment, biopsy remains within the armamentarium of
hepatologists when assessing the etiology of complex diseases
or when there are discordances between clinical symptoms and
the extent of ﬁbrosis assessed by non-invasive approaches.Methodological considerations when using non-invasive tests
The performance of a non-invasive diagnostic method is
evaluated by calculation of the area under the receiver operator
characteristic curve (AUROC), taking liver biopsy as the reference
standard. However, biopsy analysis is an imperfect reference
standard: taking into account a range of accuracies of the biopsy,
even in the best possible scenario, an AUROC >0.90 cannot be
achieved for a perfect marker of liver disease [15]. The AUROC
can vary based on the prevalence of each stage of ﬁbrosis,
described as spectrum bias [16]. Spectrum bias has important
implications for the study of non-invasive methods, particularly
in comparison of methods across different study populations. If
extreme stages of ﬁbrosis (F0 and F4) are over-represented in a
population, the sensitivity and speciﬁcity of a diagnostic method
will be higher than in a population of patients that has
predominantly middle stages of ﬁbrosis (F1 and F2). Several ways
of preventing the ‘‘spectrum bias’’ have been proposed including
the adjustment of AUROC using the DANA method (standardiza-
tion according to the prevalence of ﬁbrosis stages that deﬁne
advanced (F2–F4) and non-advanced (F0–F1) ﬁbrosis) [17,18] or
the Obuchowski measure (designed for ordinal gold standards)
[19]. What really matters in clinical practice is the number of
patients correctly classiﬁed by non-invasive methods for a
deﬁned endpoint according to the reference standard (i.e. true
positive and true negative).15 vol. 63 j 237–264
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General statements
 Even though liver biopsy has been used as the reference
method for the design, evaluation and validation of
non-invasive tests, it is an imperfect gold standard. In
order to optimize the value of liver biopsy for ﬁbrosis
evaluation, it is important to adhere to the following
recommendations: (i) sample length >15 mm by a 16G
needle; (ii) use of appropriate scoring systems according
to liver disease etiology; and (iii) reading by an experi-
enced (and if possible specialized) pathologist.
 Non-invasive tests reduce but do not abolish the need for
liver biopsy; they should be used as an integrated system
with liver biopsy according to the context.Methodology
These Clinical Practice Guidelines (CPGs) have been developed by
a panel of experts chosen by the EASL and ALEH Governing
Boards. The recommendations were peer-reviewed by external
expert reviewers and approved by EASL and ALEH Governing
Boards. The CPGs were established using data collected from
PubMed and Cochrane database searches. The CPGs have been
based, as far as possible, on evidence from existing publications,
and, if evidence was unavailable, the experts’ provide personal
experiences and opinion. When possible, the level of evidence
and recommendation are cited. The evidence and recommenda-
tions in these guidelines have been graded according to the
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) system. The strength of recommendations
thus reﬂects the quality of underlying evidence. The principles
of the GRADE system have been enunciated [20]. The quality of
the evidence in the CPG has been classiﬁed into one of three
levels: high (A), moderate (B) or low (C). The GRADE system
offers two grades of recommendation: strong (1) or weak (2)
(Table 1). The CPGs thus consider the quality of evidence: the
higher the quality of evidence, the more likely a strong recom-
mendation is warranted; the greater the variability in values
and preferences, or the greater the uncertainty, the more likely
a weaker recommendation is warranted.
The non-invasive tests CPG Panel has considered the following
questions:
What are the currently available non-invasive tests?
What are the endpoints for staging liver ﬁbrosis?Table 1. Evidence grading used for the EASL-ALEH guidelines (adapted from the GRADE
Evidence quality Notes
High
Moderate
change the estimate
Low
is likely to change the estimate. Any change of estima
Recommendation Notes
Strong
patient-important outcomes, and cost
Weak Variability in preferences and values, or more uncertai
higher cost or resource consumption
Further research is very unlikely to change our confide
Further research is likely to have an important impact 
Further research is very likely to have an important im
Factors influencing the strength of the recommendatio
238 Journal of Hepatology 2015 vHow do serum biomarkers perform for staging liver ﬁbrosis?
Do patented and non-patented serum biomarkers perform
differently?
How does transient elastography (TE) perform for staging
liver ﬁbrosis?
How do novel elastography methods perform compared to TE
for staging liver ﬁbrosis?
How does TE perform compared to serum biomarkers for stag-
ing liver ﬁbrosis?
What is the added value of combining TE and serum
biomarkers?
What are the indications for non-invasive tests for staging
liver disease in viral hepatitis?
What are the indications for non-invasive tests for staging
liver disease in non-alcoholic fatty liver disease (NAFLD)?
What are the indications for non-invasive tests for staging
liver disease in other chronic liver diseases?
How should non-invasive tests be used when deciding for
treatment in viral hepatitis?
Is there a use for non-invasive tests when monitoring treat-
ment response in viral hepatitis?
Is there a use for non-invasive tests when monitoring disease
progression in chronic liver diseases?
What is the prognostic value of non-invasive tests in chronic
liver disease?Guidelines
Currently available non-invasive methods
Non-invasive methods rely on two different approaches: a ‘‘bio-
logical’’ approach based on the quantiﬁcation of biomarkers in
serum samples or a ‘‘physical’’ approach based on the measure-
ment of liver stiffness (LS). Although these approaches are com-
plementary, they are based on different rationales. Serum
biomarkers indicate several, not strictly liver speciﬁc clinical
and serum parameters that have been associated with ﬁbrosis
stage, as assessed by liver biopsy, whereas LS corresponds to a
genuine and intrinsic physical property of liver parenchyma.
Serum biomarkers of liver ﬁbrosis
Many serum biomarkers have been proposed for staging liver
ﬁbrosis, mainly in patients with chronic hepatitis C. They aresystem).
Grading
A
B
te is uncertain
C
Grading
1
nty. Recommendation is made with less certainty, 2
nce in the estimate of effect
on our confidence in the estimate of effect and may
pact on our confidence in the estimate of effect and
n included the quality of the evidence, presumed
ol. 63 j 237–264
Table 2. Currently available serum biomarkers for non-invasive evaluation of liver ﬁbrosis in chronic liver disease.
HCV
Fibrotest® (Biopredictive, Paris, France) patented formula combining α-2-macroglobulin, γGT, apolipoprotein A1, haptoglobin, total 
bilirubin, age and gender
Forns Index = 7.811 - 3.131 x ln(platelet count) + 0.781 x ln(GGT) + 3.467 x ln(age) - 0.014 x (cholesterol)
AST to Platelet Ratio (APRI) = AST (/ULN)/platelet (109/L) x 100
FibroSpectII® (Promotheus Laboratory Inc, San Diego, USA) patented formula combining α-2-macroglobulin, hyaluronate and TIMP-1 
MP3 = 0.5903 x log(PIIINP [ng/ml]) - 0.1749 x log(MMP-1 [ng/ml])
Enhanced Liver Fibrosis score® (ELF) (Siemens Healthcare, Erlangen, Germany) patented formula combining age, hyaluronate,
MMP-3 and TIMP-1
Fibrosis Probability Index (FPI) = 10.929 + (1.827 x Ln[AST]) + (0.081 x age) + (0.768 x past alcohol use*) + (0.385 x HOMA-IR) - 
(0.447 x cholesterol)
Hepascore® (PathWest, University of Western Australia, Australia) patented formula combining bilirubin, γGT, hyaluronate, α-2-
macroglobulin, age and gender
Fibrometer® (Echosens, Paris, France) patented formula combining platelet count, prothrombin index, AST, α-2-macroglobulin, 
hyaluronate, urea and age
Lok index = -5.56 - 0.0089 x platelet (103/mm3) + 1.26 x AST/ALT ratio = 5.27 x INR 
Gotebörg University Cirrhosis Index (GUCI) = AST x prothrombin - INR x 100/platelet
Virahep-C model = -5.17 + 0.20 x race + 0.07 x age (yr) + 1.19 ln(AST [IU/L]) - 1.76 ln(platelet count [103/ml]) + 1.38 ln(alkaline phos-
phatase [IU/L])
Fibroindex = 1.738 - 0.064 x (platelets [104/mm3]) + 0.005 x (AST [IU/L]) + 0.463 x (gamma globulin [g/dl])
HALT-C model = -3.66 - 0.00995 x platelets (103/ml) + 0.008 x serum TIMP-1 + 1.42 x log(hyaluronate)
HBV
Hui score = 3.148 + 0.167 x BMI + 0.088 x bilirubin - 0.151 x albumin - 0.019 x platelet
Zeng score = -13.995 + 3.220 log(α-2-macroglobulin) + 3.096 log(age) + 2.254 log(GGT) + 2.437 log(hyaluronate)
HIV-HCV
FIB-4 = age (yr) x AST [U/L]/(platelets [109/L] x (ALT [U/L])1/2
SHASTA index = -3.84 + 1.70 (1 if HA 41-85 ng/ml, 0 otherwise) + 3.28 (1 if HA >85 ng/ml, 0 otherwise) + 1.58 (albumin <3.5 g/dl, 
0 otherwise) + 1.78 (1 if AST >60 IU/L, 0 otherwise) 
NAFLD
NAFLD Fibrosis Score (NFS) = (-1.675 + 0.037 x age (yr) + 0.094 x BMI (kg/m2) + 1.13 x IFG/diabetes (yes = 1, no = 0) + 0.99 x AST/
ALT ratio - 0.013 x platelet count (x109/L) - 0.66 x albumin [g/dl])
BARD score (BMI ≥28 = 1; AST/ALT ratio ≥0.8 = 2; diabetes = 1; score ≥2, odds ratio for advanced fibrosis = 17)
⁄Graded as 0–2.
JOURNAL OF HEPATOLOGYsummarized in Table 2. The FibroTest (proprietary formula;
Biopredictive, Paris, France, licensed under the name of
Fibrosure in the USA (LabCorp, Burlington, NC, USA)) was the
ﬁrst algorithm combining several parameters [21]. Several other
scores or algorithms have been proposed in hepatitis C virus
(HCV) [22–35], as well as in hepatitis B virus (HBV) [36,37],
human immunodeﬁciency virus (HIV)-HCV coinfection [38,39],
and NAFLD [40,41]. Four are protected by patents and
commercially available: the FibroMeter (Echosens, Paris,
France), the FibroSpectII (Prometheus Laboratory Inc. San
Diego, CA, USA), the ELF (Enhanced Liver Fibrosis Test,
Siemens Healthcare, Erlangen, Germany) and the HepaScore
(PathWest, University of Western Australia, Australia). Non-
patented methods use published models, based on routinely
available laboratory values.
The practical advantages of analyzing serum biomarkers to
measure ﬁbrosis include their high applicability (>95%) [42], their
good inter-laboratory reproducibility [43,44], and their potential
widespread availability (non-patented) (Table 3). However, none
are liver speciﬁc and their results may be inﬂuenced by changes
in clearance and excretion of each individual parameters. ForJournal of Hepatology 201instance, increased levels of hyaluronate occur in the post-pran-
dial state [45] or in aged patients with chronic inﬂammatory pro-
cesses such as rheumatoid arthritis [46]. Also, the reproducibility
of measurement of some parameters included in ‘‘indirect’’ serum
markers, such as aspartate aminotransferase (AST) levels or pla-
telet count, is questionable [47]. In addition, the interpretation
of each test requires a critical analysis in order to avoid false posi-
tive or false negative results. For instance, when using FibroTest,
the existence of hemolysis or Gilbert syndrome that can lead to
false positive results (by a decrease haptoglobin or an increase
in bilirubin, respectively) should be taken into account [48].
Similarly, acute hepatitis can produce false positive results in
the aspartate-to-platelet ratio index (APRI), Forns index, FIB-4
or FibroMeter tests, since all include serum levels of amino-
transferases in their formulas.
Liver stiffness measurement
Transient elastography
Liver ﬁbrosis can be staged using 1-dimensional ultrasound TE
(FibroScan(R), Echosens, Paris, France) [49], which measures the5 vol. 63 j 237–264 239
Table 3. Respective advantages and disadvantages of currently available non-invasive methods in patients with chronic liver disease.
Serum biomarkers Measurement of liver stiffness
Transient elastography ARFI (pSWE) 2D-SWE MR elastography
Advantages
• Good reproducibility
• High applicability (95%)
• No cost and wide availability 
(non-patented)
• Well validated
• Can be performed in the  
outpatient clinic
• Most widely used and 
validated technique: 
standard to be beaten
• User-friendly (performed 
at bedside; rapid, easy to 
learn)
• High range of values (2-75 
kPa)
• Quality criteria well defined
• Good reproducibility
• High performance for 
cirrhosis (AUROC >0.9)
• Prognostic value in 
cirrhosis
• Can be implemented on a 
regular US machine
• ROI smaller than TE but 
location chosen by the 
operator
• Higher applicability than TE 
(ascites and obesity)
• Performance equivalent 
to that of TE for significant 
fibrosis and cirrhosis
• Can be implemented on a  
regular US machine
• ROI can be adjusted in size 
and location and chosen by 
the operator 
• Measures liver stiffness in 
real-time
• High range of values (2-150 
kPa)
• Good applicability
• High performance for 
cirrhosis
• Can be implemented on a 
regular MRI machine
• Examination of the whole 
liver
• Higher applicability than  
TE (ascites and obesity)
• High performance for 
cirrhosis
Disadvantages
• Non-specific of the liver
• Unable to discriminate 
between intermediate stages 
of fibrosis
• Performance not as good as 
TE for cirrhosis
• Cost and limited availability 
(proprietary) 
• Limitations (hemolysis,  
Gilbert syndrome, 
inflammation…)
• Requires a dedicated 
device
• ROI cannot be chosen
• Unable to discriminate 
between intermediate 
stages of fibrosis
• Applicability (80%) lower 
than serum biomarker: 
(obesity, ascites, operator 
experience)
• False positive in case of 
acute hepatitis, extra-
hepatic cholestasis, liver 
congestion, food intake and 
excessive alcohol intake
• Unable to discriminate 
between intermediate 
stages of fibrosis
• Units (m/sec) different from 
that of TE (kPa)
• Narrow range of values 
•  (0.5-4.4 m/sec)
• Quality criteria not well 
defined
• Prognostic value in 
cirrhosis?
• Further validation warranted
• Unable to discriminate 
between intermediate 
stages of fibrosis
• Quality criteria not well 
defined
• Learning curve?
• Influence of inflammation?
• Further validation 
warranted especially in 
comparison with TE
• Not applicable in case of  
iron overload
• Requires a MRI facility
• Time-consuming
• Costly
ROI, region of interest.
Clinical Practice Guidelinesvelocity of a low-frequency (50 Hz) elastic shear wave propagat-
ing through the liver. This velocity is directly related to tissue
stiffness, called the elastic modulus (expressed as E = 3 qv2,
where v is the shear velocity and q is the density of tissue,
assumed to be constant). The stiffer the tissue, the faster the
shear wave propagates.
TE is performed on a patient lying supine, with the right arm
elevated to facilitate access to the right liver lobe. The tip of the
probe is contacted to the intercostal skin with coupling gel in
the 9th to 11th intercostal space at the level where a liver biopsy
would be performed. The operator, assisted by a time-motion
image, locates a liver portion at least 6 cm deep and free of large
vascular structures. The operator then presses the probe button
to start the measurements (‘‘shots’’). TE measures LS in a volume
that approximates a cylinder 1 cm wide and 4 cm long, between
25 mm and 65 mm below the skin surface. The software deter-
mines whether each measurement is successful or not. When a
shot is unsuccessful, the machine does not return a value. The
entire procedure is considered to have failed when no value is
obtained after ten shots. The ﬁnal result of a TE session can be
regarded as valid if the following criteria are fulﬁlled: 1) a num-
ber of valid shots of at least 10; 2) a success rate (the ratio of valid
shots to the total number of shots) above 60%; and 3) an
interquartile range (IQR, reﬂecting the variability of240 Journal of Hepatology 201measurements) less than 30% of the median LS measurements
(M) value (IQR/M 60.30%) [50].
The results are expressed in kilopascals (kPa), and range from
1.5 to 75 kPa with normal values around 5 kPa, higher in men and
in patients with low or high body mass index (BMI) (U-shaped
distribution) [51–54].
Advantages of TE include a short procedure time (<5 min),
immediate results, and the ability to perform the test at the bed-
side or in an outpatient clinic (Table 3). Finally, it is not a difﬁcult
procedure to learn which can be performed by a nurse or a tech-
nician after minimal training (about 100 examinations) [55].
Nevertheless, the clinical interpretation of TE results should
always be in the hands of an expert clinician and should be made
with full knowledge of patient demographics, disease etiology
and essential laboratory parameters.
Although TE analysis has excellent inter- and intra-observer
agreement [56,57] (with an intra-class correlation coefﬁcient
(ICC) of 0.98), its applicability is not as good as that of serum bio-
markers. In the largest TE series reported to date (n = 13,369
examinations), failure to obtain any measurement has been
reported in 3.1% of cases and unreliable results (not meeting
manufacturer’s recommendations) in 15.8% [58], mostly due to
patient obesity or limited operator experience. Similar results
have been reported in a large series of Asian patients (n = 3205)5 vol. 63 j 237–264
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with failure and unreliable results rates of 2.7% and 11.6%,
respectively [59].
An important question in clinical practice is whether unreli-
able results translate into decreased accuracy. It has been sug-
gested that among the recommendations, the IQR/M <30% is
the most important parameter for good diagnostic accuracy
[60,61]. In a recent study [62] in 1165 patients with chronic
liver diseases (798 with chronic hepatitis C) taking liver biopsy
as reference, TE reliability was related to two variables in
multivariate analysis: the IQR/M and LS measure. Indeed, the
presence of an IQR/M >30% and LS measure median P7.1 kPa
resulted in a lower accuracy (as determined by AUROC) than
that of the whole study population and these cases were there-
fore considered ‘‘poorly reliable’’. Conversely, the highest accu-
racy was observed in the group with an IQR/M 610%
regardless of the LS measure. Also a recent study reported a sig-
niﬁcant discrepancy in up to 20% of cases in patients without
cirrhosis between different FibroScan devices (402 vs. 502)
[63]. These results require further validation before any recom-
mendation can be made.
In order to minimize the number of patients with unreli-
able results due to obesity, a new probe (XL, 2.5 MHz trans-
ducer), allowing measurement of LS between 35 to 75 mm
depth, has been developed [64–68]. Myers et al. [66] showed
that in 276 patients with chronic liver disease (42% viral hep-
atitis, 46% NAFLD) and a BMI >28 kg/m2, measurement failures
were signiﬁcantly less frequent with the XL probe than with
the M probe (1.1% vs. 16%; p <0.00005). However, unreliable
results were still observed with the XL probe in 25% of case
instead of 50% with the M probe (p <0.00005). Also it is
important to note that stiffness values obtained with XL probe
are lower than that obtained with the M probe (by a median
of 1.4 kPa).
Apart from obese patients, TE results can also be difﬁcult to
obtain from patients with narrow intercostal space and are
nearly impossible to obtain from patients with ascites [49]. As
the liver is an organ with a distensible but non-elastic envelope
(Glisson’s capsule), additional space-occupying tissue abnor-
malities, such as edema, inﬂammation, extra-hepatic cholestasis,
or congestion, can interfere with measurements of LS, indepen-
dently of ﬁbrosis. Indeed, the risk of overestimating LS values
has been reported with other confounding factors including ala-
nine aminotransferase (ALT) ﬂares [69–71], extra-hepatic
cholestasis [72], congestive heart failure [73], excessive alcohol
intake [74–76], and food intake [77–80], suggesting that TE
should be performed in fasting patients (for at least 2 h) and
results always interpreted being aware of these potential con-
founding [81]. The inﬂuence of steatosis is still a matter of
debate with conﬂicting results: some studies suggest that
steatosis is associated to an increase in LS [82–84] whereas
others do not [85,86].Other liver elasticity-based imaging techniques
Several other liver elasticity-based imaging techniques are being
developed, including ultrasound-based techniques and 3-D mag-
netic resonance (MR) elastography [87]. Ultrasound elastography
can be currently performed by different techniques, which areJournal of Hepatology 201based on two physical principles: strain displacement/imaging
and shear wave imaging and quantiﬁcation [88]. The latter allows
a better estimation of liver tissue elasticity/stiffness, and includes
point shear wave elastography (pSWE), also known as acoustic
radiation force impulse imaging (ARFI) (Virtual touch tissue
quantiﬁcation™, Siemens; elastography point quantiﬁcation,
ElastPQ™, Philips) and 2D-shear wave elastography (2D-SWE)
(Aixplorer™ Supersonic Imagine, France). pSWE/ARFI involves
mechanical excitation of tissue using short-duration (262 lsec)
acoustic pulses that propagate shear waves and generate
localized, l-scale displacements in tissue [89]. The shear wave
velocity (expressed in m/sec) is measured in a smaller region
than in TE (10 mm long and 6 mm wide), but the exact location
where measurements are obtained can be selected by the opera-
tor under B-mode visualization. A major advantage of pSWE/ARFI
is that it can be easily implemented on modiﬁed commercial
ultrasound machines (Acuson 2000/3000 Virtual Touch™
Tissue Quantiﬁcation, Siemens Healthcare, Erlangen, Germany;
ElastPQ, iU22xMATRIX, Philips, Amsterdam, The Netherlands).
Its failure rate is signiﬁcantly lower than that of TE (2.9% vs.
6.4%, p <0.001), especially in patients with ascites or obesity
[90]. Also its reproducibility is good, with ICC ranging from 0.84
to 0.87 [91–93]. However, like TE, pSWE/ARFI results are inﬂu-
enced by food intake [94] as well as necro-inﬂammatory activity
and the serum levels of aminotransferases [95], both of which
lead to an overestimation of liver ﬁbrosis and have to be taken
into account when interpreting the results. LS values obtained
with pSWE/ARFI, in contrast to TE values, have a narrow range
(0.5–4.4 m/sec). This limits the deﬁnitions of cut-off values for
discriminating certain ﬁbrosis stages and thus for making
management decisions. Finally, quality criteria for correct inter-
pretation of pSWE results remain to be deﬁned.
2D-SWE is based on the combination of a radiation force
induced in tissues by focused ultrasonic beams and a very high
frame rate ultrasound imaging sequence capable of catching in real
time the transient propagation of resulting shear waves [96]. The
size of the region of interest can be chosen by the operator.
2D-SWE has also the advantage of being implemented on a com-
mercially ultrasound machine (Aixplorer, Supersonic Imagine,
Aix en Provence, France) with results expressed either in m/sec
or in kPa at a wide range of values (2–150 kPa). Its failure rate is
signiﬁcantly lower than that of TE [97–99], particularly in patients
with ascites [98,99], but not in obese patientswhen the XL probe is
used for TE (10.4% vs. 2.6%, respectively) [100]. Similar to pSWE/
ARFI, quality criteria for 2D-SWE remain to be deﬁned.
MR elastography uses a modiﬁed phase-contrast method to
image the propagation characteristics of the shear wave in the
liver [101]. Elasticity is quantiﬁed by MR elastography (expressed
in kPa) using a formula that determines the shear modulus,
which is equivalent to one-third the Young’s modulus used with
TE [102]. The theoretical advantages of MR elastography include
its ability to analyze almost the entire liver and its good
applicability in patients with obesity or ascites. However, MR
elastography remains currently too costly and time-consuming
to be used in routine practice and cannot be performed in livers
of patients with iron overload, because of signal-to-noise
limitations.5 vol. 63 j 237–264 241
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Recommendations
• Non-invasive tests should always be interpreted 
by specialists in liver disease, according to the 
clinical context, considering the results of other tests 
(biochemical, radiological and endoscopic) and taking 
into account the recommended quality criteria for each 
test and its possible pitfalls (A1)
• Serum biomarkers can be used in clinical practice 
due to their high applicability (>95%) and good inter-
laboratory reproducibility. However, they should be 
preferably obtained in fasting patients (particularly 
those including hyaluronic acid) and following the 
manufacturer’s recommendations for the patented 
tests (A1)
• TE is a fast, simple, safe and easy to learn procedure 
that is widely available. Its main limitation is the 
impossibility of obtaining results in case of ascites or 
morbid obesity and its limited applicability in case of 
obesity and limited operator experience (A1)
• TE should be performed by an experienced operator 
(>100 examinations) following a standardized protocol 
with the patient, fasting for at least 2 hours, in the 
supine position, right arm in full abduction, on the mid-
axillary line with the probe-tip placed in the 9th to 11th
intercostal space with a minimum of 10 shots (A1)
• Correct interpretation of TE results in clinical practice 
must consider the following parameters:
- IQR/ median value (<30%),
- Serum aminotransferases levels (<5 x ULN),
- BMI (use XL probe above 30 kg/m2 or if skin-to-  
capsule distance is >25 mm),
- Absence of extra-hepatic cholestasis,
- Absence of right heart failure, or other causes of 
congestive liver
- Absence of ongoing excessive alcohol intake
         (A1)
• Although alternative techniques, such as pSWE/ARFI 
or 2D-SWE seem to overcome limitations of TE, their 
quality criteria for correct interpretation are not yet well 
defined (A1)
• At present correct interpretation of pSWE/ARFI results 
in clinical practice should systematically take into 
account the potentially confounding parameter:
- fasting for at least 2 hours, transaminases levels 
(<5 x ULN), absence of extra-hepatic cholestasis and 
absence or right heart failure (B1) 
• MR elastography is currently too costly and time-
consuming for routine clinical practice use and seems 
more suited for research purposes (A1)Endpoints for staging liver ﬁbrosis
In patients with viral hepatitis and HIV-HCV coinfection, the
clinically relevant endpoints are: (1) detection of signiﬁcant
ﬁbrosis (METAVIR, F P2 or Ishak, P3), which indicates that
patients should receive antiviral treatment. However, with the242 Journal of Hepatology 201availability of novel antiviral agents able to achieve sustained
virological response (SVR) rates above 90% with limited side
effects, it is likely that signiﬁcant ﬁbrosis will no longer represent
an important decision making endpoint in HCV-infected patients.
(2) Detection of cirrhosis (METAVIR, F4 or Ishak, 5–6) indicates
that patients should not only potentially be treated for longer
duration/different regimens in HCV but also monitored for com-
plications related to portal hypertension (PH) and regularly
screened for hepatocellular carcinoma (HCC). In NAFLD,
representing another major etiology of chronic liver disease, the
presence of signiﬁcant ﬁbrosis does not represent a relevant end-
point in the absence of standardized treatment regimens.
However, detection of septal (advanced) ﬁbrosis-cirrhosis seems
clinically more relevant in NAFLD patients. In alcoholic liver dis-
ease (ALD), cholestatic liver diseases, and other etiologies, cirrho-
sis represents the most relevant clinical endpoint.
Recommendations
• In patients with viral hepatitis (including HIV/HCV 
coinfection), there are two clinically relevant endpoints: 
the detection of significant fibrosis and the detection 
of cirrhosis. However, with the availability of highly 
effective novel antiviral agents significant fibrosis 
might no longer represent a relevant endpoint in HCV-
infected patients whereas detection of cirrhosis is still 
important to guide treatment with novel antiviral agents 
(A1)
• In patients with NAFLD, detection of cirrhosis 
represents the most important endpoint. The clinical 
importance of detecting milder stages of liver fibrosis in 
NAFLD remains to be defined (A1)
• In patients with other etiologies of chronic liver 
diseases, detection of cirrhosis represents the most 
relevant clinical endpoint (A1) 
• Detection of cirrhosis indicates that patients should be 
monitored for complications related to PH and regularly 
screened for HCC (A1)Performance of serum biomarkers for staging liver ﬁbrosis
The diagnostic performances of serum biomarkers of ﬁbrosis are
summarized in Table 4. Overall, biomarkers are less accurate in
detecting intermediate stages of ﬁbrosis than cirrhosis. The most
widely used and validated are the APRI (a free non-patented
index) and the FibroTest (a patented test that is not widely
available), mainly in viral hepatitis C. A recent systematic review
including 172 studies conducted in hepatitis C [103] reported
median AUROCs of 0.79 and 0.86 for FibroTest and of 0.77 and
0.84 for APRI, for signiﬁcant ﬁbrosis and cirrhosis, respectively.
A meta-analysis by the developer [104] that analyzed data from
6378 subjects (individual data from 3282 subjects) who received
the FibroTest and biopsies (3501 with HCV infection and 1457
with HBV) found that the mean standardized AUROC for diagno-
sis of signiﬁcant ﬁbrosis was 0.84, without signiﬁcant differences
between patients with HCV (0.85) and HBV (0.80). Another meta-
analysis [105] analyzed results from 6259 HCV patients from 335 vol. 63 j 237–264
Table 4. Diagnostic performance of serum biomarkers of ﬁbrosis for signiﬁcant ﬁbrosis (F P2) and cirrhosis (F4) in patients with chronic liver disease.
Biomarkers Etiologies Year Patients
(n)
F≥2
 (%)
F4
 (%)
Cut-offs AUROC Se
(%)
Sp
(%)
CC
(%)
FibroTest® [21]
Forns Index [22]
APRI [23]
FibroSpectII® [24]
MP3 [25]
FPI [26]
Hepascore® [27]
Lok index [28]
GUCI [29]
ViraHep-C [30]
Fibroindex [31]
FIB-4 [32]
HALT-C model [33]
Hui Score [36]
Zeng score [37]
SHASTA [38]
FIB-4 [39]
ELF® [34]
Fibrometer® [35]
NFS [40]
BARD score [41]
HCV
HCV
HCV
HCV
HCV
HCV
HCV
HCV
HCV
HCV
HCV
HCV
HCV
HBV
HBV
HIV-HCV
HIV-HCV
Mixed
Mixed
NAFLD
NAFLD
2001
2002
2003
2004
2004
2005
2005
2005
2005
2006
2007
2007
2008
2005
2005
2005
2006
2004
2005
2007
2008
339
476
270
696
194
302
211
1141
179
398
360
830
512
235
372
95
832
1021/496**
598/503**
733
669
80
26
50
52
45
48
57
 
37
50
25
58
27
40
56
17
16
38
12
17*
38
22*
12
27*
30*
>0.48
<4.2 >6.9
≤0.5 >1.5
<1.0 ≥2.0
>0.36
<0.3 >0.4
≤0.2 ≥0.8
≥0.5
>0.84
<0.2 ≥0.5
>0.1
≤0.22 >0.55
≤1.25 ≥2.25
<1.45 >3.25
<0.2 ≥0.5
≤0.15 >0.5
<3.0 >8.7
<0.3 >0.8
<1.45 >3.25
0.102
n.a.
n.a.
<-1.455 >0.676 
≥2
0.87
0.81
0.80
0.89
0.83
0.82
0.77
0.82
0.89
0.81
0.85
0.83
0.83
0.85
0.81
0.79
0.77
0.87
0.76
0.78
0.89
0.89
0.82
0.81
75
30-94
41-91
57-89
77
35-65
42-85
63
71
40-98
80
51-90
30-40
38-74
47-88
37-88
40-98
15-88
70
87
n.a.
80
43-77
n.a.
85
51-95
47-95
75-93
73
85-96
48-98
89
89
53-99
70
54-90
97-97
81-98
45-92
50-88
28-90
72-100
97
51
n.a.
84
97-97
n.a.
46
45
44
72
75
n.a.
40-49
92
n.a.
52
n.a.
52
35
68
48
49
35
42
62
n.a.
n.a.
82
68
n.a.
HCV, chronic hepatitis C; HBV, chronic hepatitis B; NAFLD, non-alcoholic fatty liver disease; AUROC, area under ROC curve; Se, sensitivity; Sp, speciﬁcity; CC, correctly
classiﬁed: true positive and negative; n.a., not available.
⁄F3F4.
⁄⁄HCV patients.
JOURNAL OF HEPATOLOGYstudies; the mean AUROC values of APRI in diagnosis of signiﬁ-
cant ﬁbrosis and cirrhosis were 0.77 and 0.83, respectively.
Another meta-analysis of APRI in 1798 HBV patients found mean
AUROC values of 0.79 and 0.75 for signiﬁcant ﬁbrosis and cirrho-
sis, respectively [106]. In the largest comparative study to date
(n = 510 patients monoinfected with hepatitis B or C matched
on ﬁbrosis stage), overall diagnostic performances of blood tests
(FibroTest, FibroMeter, and HepaScore) were similar between
hepatitis B and C with AUROC ranging from 0.75 to 0.84 for sig-
niﬁcant ﬁbrosis, 0.82 to 0.85 for extensive ﬁbrosis and 0.84 to
0.87 for cirrhosis, respectively [107].
In HIV-HCV coinfected patients, performance of non-patented
tests (e.g., APRI, FIB-4, and the Forns index) for predicting ﬁbrosis
seems less accurate than in HCV-monoinfected patients: they are
accurate for the diagnosis of cirrhosis, but relatively inaccurate
for the diagnosis of signiﬁcant ﬁbrosis [108–110]. As for patented
tests, such as FibroTest, FibroMeter, and HepaScore, they out-
perform the non-patented tests in HIV-HCV coinfection, particu-
larly for signiﬁcant ﬁbrosis [111,112]. Importantly, one should be
aware of false positive results with APRI and FIB-4 (related to
HIV-induced thrombocytopenia) as well as with FibroTest and
HepaScore (related to hyperbilirubinemia induced by the use
of antiretroviral treatment such as atanazavir) or FibroTest
and Forns Index (related to increase in c-glutamyl transferase
induced by nevirapine) [111].
In patients with NAFLD, the NAFLD ﬁbrosis score [40] is
currently the most studied [85,113–118] and validated bio-
marker [119]. The NAFLD ﬁbrosis score seems to perform
better in Caucasians than Asians, probably related to the
ethical difference in fat distribution and its inﬂuence on the
BMI [102].Journal of Hepatology 201Recommendations
• Serum biomarkers of fibrosis are well validated in 
patients with chronic viral hepatitis (with more evidence 
for HCV than for HBV and HIV/HCV coinfection). They 
are less well validated in NAFLD and not validated in 
other chronic liver diseases (A1)
• Their performances are better for detecting cirrhosis 
than significant fibrosis (A1)
• Caution is needed in patients with HIV-HCV coinfection 
because of the risk of false positive results related
to HIV-induced thrombocytopenia, antiretroviral 
treatment-induced hyperbilirubinemia or increased 
serum γ-glutamyl transferase levels (A2)
• FibroTest®, APRI and NAFLD fibrosis score are the 
most widely used and validated patented and non-
patented tests (A2) Comparative performance of patented and non-patented serum
biomarkers for staging liver ﬁbrosis
When compared and validated externally in patients with hep-
atitis C [120–125], the different patented tests had similar levels
of performance in diagnosis of signiﬁcant ﬁbrosis. In the largest
independent study (1370 patients with viral hepatitis; 913 HCV5 vol. 63 j 237–264 243
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and 284 HBV patients), which prospectively compared the
widely used patented tests (FibroTest, FibroMeter, and
HepaScore) with the non-patented test (APRI), the AUROC val-
ues for signiﬁcant ﬁbrosis ranged from 0.72 to 0.78 with no sig-
niﬁcant differences among scores [124]. In patients with
cirrhosis, the AUROC values were higher for all tests, ranging
from 0.77 to 0.86, with no signiﬁcant differences among the
tests. Although non-patented tests such as the Forns index,
FIB-4, and APRI were not as accurate as patented tests [125],
there are no additional costs, they are easy to calculate, and
are widely available.Table 5. Diagnostic performance of TE for signiﬁcant ﬁbrosis (F P2) and cirrhosis (F
Authors Etiologies Year Patient
(n)
F≥2
(%)
F
(
Castera et al. [126] HCV 2005 183 74
2
Ziol et al. [127] HCV 2005 251 65
1
Arena et al. [86] HCV 2008 150 56
1
Lupsor et al. [128] HCV 2008 324 65
2
Wang et al. [134] HCV 2009 214 42
1
Degos et al. [124] HCV 2010 913 62
1
Zarski et al. [125] HCV 2012 382 47
1
Coco et al. [69] HBV (HCV) 2007 228 62
5
Oliveri et al. [130] HBV 2008 188 26
2
Marcellin et al. [131] HBV 2009 173 50
8
Chan et al. [132] HBV 2009 161 2
Kim et al. [133] HBV 2009 91 4
Wang et al. [134] HBV 2009 88 42
1
Degos et al. [124] HBV 2010 284 42
1
Sporea et al. [135] HBV 2010 140 76
5
Cardoso et al. [136] HBV 2012 202 42
8
Goyal et al. [137] HBV 2013 357 25
6
Afdhal et al. [129] HCV/HBV 2015 560** 66.7
1
HCV, chronic hepatitis C; HBV, chronic hepatitis B; AUROC, area under ROC curve; Se, sen
available.
⁄More than half of patients with «clinical» cirrhosis; adapted to ALT levels.
⁄⁄Validation cohort: HCV 92%; HBV 8%.
aAdapted to LT levels.
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• When compared in HCV patients, the different 
patented tests have similar levels of performance in 
diagnosing significant fibrosis and cirrhosis (A1)
• Although non-patented tests might have lower 
diagnostic accuracy than patented tests, they are not 
associated with additional costs, are easy to calculate, 
and are widely available (A2)4) in patients with viral hepatitis B and C.
4
%)
Cut-offs
(kPa)
AUROC Se
(%)
Sp
(%)
CC
(%)
5
7.1
12.5
0.83
0.95
67
87
89
91
73
90
8.6 0.79 56 91 68
9 14.6 0.87 86 96 94
7.8 0.91 83 82 83
9 14.8 0.98 94 92 92
7.4 0.86 76 84 79
1 11.9 0.94 87 91 90
9.5 0.82 70 83 n.a.
9 12 0.93 79 85 n.a.
5.2 0.75 90 32 57
4 12.9 0.90 72 89 87
5.2 0.82 97 35 64
4 12.9 0.93 77 90 88
8.3 0.93 85 91 87
0* 14.0 0.96 78 98 88
7.5 0.97 94 88 90
0* 11.8 0.97 86 96 94
7.2 0.81 70 83 76
11.0 0.93 93 87 94
5 12-13.4a 0.93 98 75 85
3 9.7 0.80 82 59 62
8.0 0.86 80 77 n.a.
9 10.0 0.89 85 88 n.a.
5.2 0.78 89 38 59
0 12.9 0.85 52 93 89
7.0 0.65 59 70 n.a.
13.6 0.97 86 99 n.a.
7.2 0.87 74 88 82
11.0 0.93 75 90 89
6.0 0.84 82 67 n.a.
11 0.93 81 95 n.a.
8.4 0.73 58 75 70
4.8 12.8 0.90 76 85 80
sitivity; Sp, speciﬁcity; CC, correctly classiﬁed: true positive and negative; n.a, not
5 vol. 63 j 237–264
Table 6. Diagnostic performance of TE for F P2 and F4 in chronic liver diseases other than viral hepatitis.
Authors Etiologies Year Patient
(n)
F≥2
(%)
F4
(%)
Cut-offs
(kPa)
AUROC Se
(%)
Sp
(%)
CC
(%)
Corpechot et al. [163] PBC-PSC 2006 95 60
16
7.3
17.3
0.92
0.96
84
93
87
95
75
95
Corpechot et al. [164] PBC 2012 103 50
14.5
8.8
16.9
0.91
0.99
67
93
100
99
84
98
Ganne-Carrie et al. [144] Mixed 2006 1007 15 14.6 0.95 79 95 92
Foucher et al. [162] Mixed 2007 354 13 17.6 0.96 77 97 n.a.
Fraquelli et al. [56] Mixed 2007 200 50
12
7.9
11.9
0.86
0.90
72
91
84
89
n.a.
n.a.
Nguyen-Khac et al. [165] ALD 2008 103 75
32
7.8
19.5
0.91
0.92
80
86
91
84
n.a.
n.a.
Nahon et al. [151] ALD 2008 147  54 22.7 0.87 84 83 n.a.
Yoneda et al. [156] NAFLD 2008 97 50  
9
6.6
17.0
0.86
0.99
88
100
74
97
n.a.
n.a.
Nobili et al. [157] NAFLD 2008 50 24 7.4 0.99 100 92 n.a.
Lupsor et al. [158] NAFLD 2010 72 25 6.8 0.79 67 84 75
Wong et al. [85] NAFLD 2010 246 41
10
7.0
10.3
0.84
0.95
79
92
76
88
n.a.
n.a.
Gaia et al. [82] NAFLD 2011 72 46
12.5
7.0
10.5
0.80
0.94
76
78
80
96
78
80
Petta et al. [159] NAFLD 2011 169 47 7.25 0.79 69 70 70
Myers et al. [66] NAFLD 2012 75 n.a.
n.a.
7.8
22.3
0.86
0.88
84
80
79
91
n.a.
n.a.
Wong et al. [68] NAFLD 2012 193 45
13
7.0
10.3
0.83
0.89
79
81
64
83
n.a.
n.a.
coholic fatty liver disease; ALD, alcoholic liver disease.
ed: true positive and negative; n.a., not available.
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AUROC, area under ROC curve; Se, sensitivity; Sp, speciﬁcity; CC, correctly classiﬁPerformances of TE for diagnosing signiﬁcant ﬁbrosis and cirrho-
sis are summarized in Table 5 (viral hepatitis) & Table 6 (non-vi-
ral hepatitis). The two index studies suggesting the interest of TE
in the assessment of liver ﬁbrosis have been conducted in
patients with chronic hepatitis C [126,127]. LS values strongly
correlated with METAVIR ﬁbrosis stages. However, it should be
emphasized that despite high AUROC values, a substantial over-
lap of LS values was observed between adjacent stages of hepatic
ﬁbrosis, particularly for lower ﬁbrosis stages. Many other groups
have since conﬁrmed these results [86,124,125,128,129], also in
patients with hepatitis B [69,124,129–137] as well as in patients
with HIV-HCV coinfection [138–143].
TE is a reliable method for the diagnosis of cirrhosis in
patients with chronic liver diseases, better at ruling out than rul-
ing in cirrhosis (negative and positive predictive values 96% and
74%) [144]. TE more accurately detects cirrhosis (AUROC values,
0.80–0.99; correct classiﬁcation ranging from 80% to 98%) than
signiﬁcant ﬁbrosis (AUROC values, 0.65–0.97; correct classiﬁca-
tion from 57% to 90%) (Table 5 and Table 6). Several meta-ana-
lyzes [145–149] have conﬁrmed the better diagnostic
performance of TE for cirrhosis than for ﬁbrosis, with mean
AUROC values of 0.94 and 0.84, respectively [147]. In a recent
meta-analysis of 18 studies including 2772 HBV patients [150],
mean AUROC values for diagnosing cirrhosis and signiﬁcant ﬁbro-
sis were 0.93 and 0.86, respectively. However, we are still lacking
a meta-analysis of data from individual patient data.
Different cut-offs have been proposed for cirrhosis according
to etiologies ranging from 9.7 kPa in HBV [133] to 22.7 kPa inJournal of Hepatology 201ALD [151]. However, it must be kept in mind that these cut-off
values have been deﬁned in a single population using ROC curves
in order to maximize sensitivity and speciﬁcity – and not applied
to a validation cohort. Difference between cut-offs may be simply
related to difference in cirrhosis prevalence in the studied pop-
ulations (ranging from 8% to 54%; Tables 5 and 6), known as
the spectrum bias [16,17]. Based on a meta-analysis, some
authors have proposed an optimal cut-off of 13 kPa for the
diagnosis of cirrhosis [147]. However, the cut-off choice must
also consider the pre-test probability of cirrhosis in the target
population (varying from less than 1% in the general population
to 10% to 20% in tertiary referral centres). For instance, it has been
shown that in a population with a pre-test probability of 13.8%, at
a cut-off <7 kPa, cirrhosis probability ranged from 0% to 3%
whereas at a cut-off >17 kPa cirrhosis probability was 72% [124].
When compared, the performances of TE have been shown
to be similar between patients with HBV and HCV [135,136].
Serum levels of aminotransferases should always be taken into
account when interpreting results from TE, especially in patients
with hepatitis B (who might have ﬂares) [152]. To avoid the risk
of false positive results, some authors have proposed to adapt
TE cut-offs based on levels of ALT [132], a strategy that might
not apply to patients with ﬂuctuating levels of ALT or hepatitis
ﬂares (Table 5). Conversely, in hepatitis e antigen (HBeAg)-
negative patients with normal levels of ALT, non-invasive
methods, particularly TE, could be used as adjunct tools to mea-
sure HBV DNA, to follow inactive carriers or better identify
patients who require liver biopsy (those with ongoing disease
activity or signiﬁcant ﬁbrosis, despite normal levels of ALT)
[130,153–155].5 vol. 63 j 237–264 245
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TE has also been investigated in NAFLD patients but in a smal-
ler number of studies [66,68,82,85,156–159] (Table 6). Like in
viral hepatitis, TE performances are better for cirrhosis than for
signiﬁcant ﬁbrosis with AUROCs ranging from 0.94 to 0.99 and
from 0.79 to 0.99, respectively. However, the performance of TE
in NAFLD deserves several comments: Firstly, these studies have
been conducted in heterogeneous and special populations such
as Asian patients or children with low BMI (<28 kg/m2); secondly,
most of them are underpowered with small sample size
(<100 patients) and very few patients with cirrhosis; thirdly, the
histological scoring systems such as those proposed by Brunt
et al. [160] or Kleiner et al. [161] and endpoints (signiﬁcant ﬁbrosis
or severe ﬁbrosis) were heterogeneous in most studies evaluating
ﬁbrosis by TE in NAFLD. These differences in the study designs are
likely the explanation for the observed differences among pro-
posed cut-offs for a given endpoint (ranging for instance from
10.3 to 22.3 kPa for cirrhosis) (Table 6), known as the spectrum
bias [16,17]. Finally, all these studies have been conducted in ter-
tiary referral centres with a higher proportion of patients with
severe ﬁbrosis than in the general population, making it difﬁcult
to extrapolate the performance of TE in detecting cirrhosis in large
populations. Nevertheless, TE could be of interest to exclude con-
ﬁdently severe ﬁbrosis and cirrhosis with high negative predictive
value (around 90%) in NAFLD patients [85].
TE has also been evaluated in a variety of chronic liver dis-
eases [56,144,162], as well as in primary biliary cirrhosis (PBC)
and primary sclerosing cholangitis (PSC) [163,164], and ALD
[151,165] (Table 6). However, in the latter it has been suggested
by several groups that the presence of alcoholic hepatitis may
inﬂuence LS results [74–76] and thus, TE should be ideally per-
formed only after alcohol withdrawal in order to improve
diagnostic accuracy.
Recommendations
• TE can be considered the non-invasive standard for 
the measurement of LS (A1)
• TE is well validated in viral hepatitis with performance 
equivalent in hepatitis B and C and in HIV-HCV 
coinfection (A1) 
• TE is less well validated in NAFLD and in other chronic 
liver diseases (A1)
• TE performs better for detection of cirrhosis than for 
detection of significant fibrosis (A1)
• TE is a reliable method for the diagnosis of cirrhosis 
in patients with chronic liver diseases, that generally 
performs better at ruling out than ruling in cirrhosis 
(with negative predictive value higher than 90%) (A1)Performance of other techniques for staging liver ﬁbrosis
Point shear wave elastography using acoustic radiation force impulse
quantiﬁcation
Performances of pSWE/ARFI (Siemens) for diagnosing signiﬁcant
ﬁbrosis and cirrhosis are summarized in Table 7. Most studies246 Journal of Hepatology 201evaluated patients with mixed chronic liver disease with viral
hepatitis being the predominant liver disease [166–177].
Similar to TE, pSWE/ARFI more accurately detects cirrhosis
(AUROC values: 0.81–0.99) than signiﬁcant ﬁbrosis (AUROC
values: 0.77–0.94). The largest study evaluating pSWE/ARFI for
staging of chronic hepatitis C was a retrospective pooled
analysis of 914 international patient data [178], part of which
were published in smaller single centre studies previously
[166,167,170,171,174,179]. It reported sensitivity and speciﬁcity
of pSWE/ARFI for the diagnosis of signiﬁcant ﬁbrosis of 0.69 and
0.80 and for the diagnosis of liver cirrhosis of 0.84 and 0.76,
respectively [178].
Meta-analyzes have conﬁrmed the better diagnostic perfor-
mance of pSWE/ARFI for cirrhosis than for ﬁbrosis [180,181]. In
a pooled meta-analysis including 518 individual patients with
chronic liver disease (83% with viral hepatitis) mean AUROCs
were 0.87 for the diagnosis of signiﬁcant ﬁbrosis, and 0.93 for
the diagnosis of liver cirrhosis [180]. In a meta-analysis of 36
studies (21 full paper publications and 15 abstracts) comprising
3951 patients mean AUROCs were 0.84 (diagnostic odds ratio
[DOR]: 11.54) for the diagnosis of signiﬁcant ﬁbrosis, and 0.91
(DOR: 45.35) for the diagnosis of liver cirrhosis [181]. Cut-off val-
ues suggested in the two meta-analyzes were 1.34–1.35 m/sec
for the diagnosis of signiﬁcant ﬁbrosis and 1.80–1.87 m/sec for
the diagnosis of cirrhosis. Only few studies have evaluated
pSWE/ARFI in chronic hepatitis B [182,183] and reported com-
parable results as for chronic hepatitis C and mixed chronic liver
disease.
In a few studies pSWE/ARFI has also been investigated in
NAFLD [184–187]. Such as in viral hepatitis, pSWE/ARFI perfor-
mances are better for severe ﬁbrosis and cirrhosis than for signiﬁ-
cant ﬁbrosis with AUROCs ranging from 0.91 to 0.98 and from
0.66 to 0.86, respectively. Interestingly, 80% of patients with
BMI between 30 and 40 kg/m2 and 58% of patients with BMI
>40 kg/m2 could be successfully evaluated using pSWE/ARFI
[186]. Finally, pSWE/ARFI has also been evaluated in a variety
of chronic liver diseases (ALD, PBC, PSC, and autoimmune hepati-
tis (AIH)). However, since most studies included mixed chronic
liver diseases with predominantly viral hepatitis, the value of
pSWE/ARFI for less common etiologies of chronic liver disease
needs further evaluation.
2D-shear wave elastography
Only few studies [96,97,188,189] have evaluated 2D-SWE for the
staging of liver ﬁbrosis, two of which used liver biopsy as refer-
ence method [97,189]. In a pilot study in 121 patients with
chronic hepatitis C (METAVIR ﬁbrosis stage 41% F0/F1, 27% F2,
12% F3, and 20% F4), AUROCs of 2D-SWE for the diagnosis of sig-
niﬁcant ﬁbrosis and cirrhosis were 0.92 and 0.98, respectively
[189]. In another study in 226 patients with chronic hepatitis B
(METAVIR ﬁbrosis stage 17% F0, 23% F1, 25% F2, 20% F3, and
15% F4), 2D-SWE had AUROCS of 0.88 and 0.98 for the diagnosis
of signiﬁcant ﬁbrosis and cirrhosis, respectively [97]. Sensitivities
and speciﬁcities were 85% and 92% for the diagnosis of signiﬁcant
ﬁbrosis using a cut-off of 7.1 kPa, and 97% and 93% for the diagno-
sis of cirrhosis using a cut-off of 10.1 kPa.
Other elastography methods such as strain elastography (a
quasi-static technique) are available, but data for the staging of
liver ﬁbrosis are insufﬁcient and seem to suggest that strain elas-
tography has a worse diagnostic performance as compared to
shear wave elastography [190].5 vol. 63 j 237–264
Table 7. Diagnostic performance of pSWE using ARFI for F P2 and F4 in chronic liver diseases.
Authors Etiologies Year Patients
(n)
F≥2
(%)
F4
(%)
Cut-offs
(m/s)
AUROC Se
(%)
Sp
(%)
CC
(%)
Fierbinteanu-Braticevici et al. [166] HCV 2009 100 87
27
1.22
1.94
0.91
0.99
100
100
71
98
96
99
Friedrich-Rust et al. [167] HCV, HBV 2009 106 59
10
1.37
1.75
0.82
0.91
69
83
92
90
78
91
Lupsor et al. [168] HCV 2009 112 59
38
1.34
2.11
0.86
0.94
68
80
93
95
78
89
Goertz et al. [169] HCV, HBV 2010 79 39
16
1.24
1.73
0.85
0.87
86
100
70
78
76
82
Takahashi et al. [170] Mixed 2010 80 64
31
1.34
1.81
0.94
0.96
91
94
80
87
87
89
Palmeri et al. [186] NAFLD 2011 172 30* 4.24** 0.91 90 90 90
Piscaglia et al. [171] Mixed 2011 122 64
39
1.63
1.87
0.79
0.91
59
81
100
91
74
87
Rizzo et al. [172] HCV 2011 146 63
22
1.31
2.11
0.86
0.89
81
83
70
86
77
85
Rifai et al. [173] Mixed 2011 122 n.a. 1.60 0.82 80 92 n.a.
Sporea et al. [174] Mixed 2011 114 61
31
1.27
1.71
0.89
0.93
89
93
68
87
81
89
Sporea et al. [175] Mixed 2011 223 52
2
1.41
1.82
0.77
0.92
71
100
78
88
74
88
Toshima et al. [176] Mixed 2011 103 66
27
1.52
1.79
0.81
0.87
75
86
76
79
75
81
Colombo et al. [177] Mixed 2012 91 35
14
1.44
1.71
0.81
0.93
84
100
70
77
75
80
Friedrich-Rust et al. [180] HBV 2013 131 24 1.39 0.73 50 90 80
HCV, chronic hepatitis C; HBV, chronic hepatitis B; NAFLD, non-alcoholic fatty liver disease; AUROC, area under ROC curve; Se, sensitivity; Sp, speciﬁcity; CC, correctly
classiﬁed: true positive and negative; n.a., not available.
⁄F3–F4.
⁄⁄Transformed in kPa.
JOURNAL OF HEPATOLOGYTransient elastography vs. other techniques
Studies comparing TE and pSWE using ARFI show varying results.
While many studies reported comparable results for both meth-
ods [167,174,179,191,192], some studies report better results for
ARFI [172] and others better results for TE [168,174], respec-
tively. In a recent meta-analysis [90] including 13 studies
(n = 1163 patients) comparing pSWE using ARFI with TE (11
full-length articles and two abstracts), no signiﬁcant difference
in DOR were found between ARFI and TE. Summary sensitivities
and speciﬁcities for the diagnosis of signiﬁcant ﬁbrosis were
0.74 and 0.83 for ARFI and 0.78 and 0.84 for TE, respectively
and 0.87 and 0.87 for ARFI and 0.89 and 0.87 for TE for the
diagnosis of cirrhosis, respectively.
2D-SWE has been compared to TE in only three studies
[97,100,189]. In chronic hepatitis C [189], AUROCs of SWE were
signiﬁcantly higher than with TE for the diagnosis of signiﬁcant
ﬁbrosis (0.92 vs. 0.84, respectively; p = 0.002) but not for cirrhosis
(0.98 vs. 0.96, p = 0.48). In chronic hepatitis B, AUROCs for SWE
were signiﬁcantly higher for both signiﬁcant ﬁbrosis (0.88 vs.
0.78) and cirrhosis (0.98 vs. 0.92) [97]. In 349 patients with
chronic liver disease [100], SWE had a higher accuracy than TE
for the diagnosis of severe ﬁbrosis (PF3) (p = 0.0016), and a
higher accuracy than pSWE using ARFI for the diagnosis of signiﬁ-
cant ﬁbrosis (PF2) (p = 0.0003).
MR elastography has been compared to TE in patients with
chronic liver diseases in three studies with conﬂicting results
[193–195]. Two studies (a pilot Belgian study [193] and a
Japanese retrospective study [195] in 96 and 113 patients withJournal of Hepatology 201chronic liver disease) suggested that MR elastography might be
more accurate than TE in diagnosis of signiﬁcant ﬁbrosis whereas
another study from the Netherlands [194] in 85 patients with
viral hepatitis reported similar accuracy for signiﬁcant ﬁbrosis.
Further data are required to evaluate if MR elastography has
superior accuracy for detecting signiﬁcant ﬁbrosis and cirrhosis
as compared to TE, pSWE/ARFI, or 2D-SWE.
Recommendations
• pSWE/ARFI performs better for detecting cirrhosis than 
significant fibrosis and is better validated in chronic 
hepatitis C than for hepatitis B, HIV-HCV coinfection, 
NAFLD and other liver diseases (A1)
• pSWE/ARFI shows equivalent performance to TE for 
detecting significant fibrosis and cirrhosis (A1)
• 2D-SWE is a promising technique that is currently 
under investigation. It seems to be at least equivalent 
to TE and pSWE/ARFI for non-invasive staging of liver 
fibrosis in viral hepatitis (B1)
• Comparison between MR elastography and TE has 
provided conflicting results. Further data are needed 
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Comparison of performance of TE and serum biomarkers for staging 
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Fig. 1. Proposed algorithm for the use of non-invasive tests in treatment-
naive patients with Hepatitis C with or without HIV coinfection.liver ﬁbrosis
Many studies have compared the performances of TE and serum
biomarkers, mostly in viral hepatitis [124–126,143,196–203] but
also in NAFLD and ALD [85,165]. TE and serum biomarkers have
been shown to have equivalent performance for detecting signiﬁ-
cant ﬁbrosis [124–126] but TE outperforms serum biomarkers for
detecting cirrhosis [124,196,199]. However, given the lower
applicability of TE (80% vs. 95% for serum biomarkers), perfor-
mance could ﬁnally not differ for intention-to-diagnose analysis
[125].
Recommendations
• TE and serum biomarkers have equivalent 
performance for detecting significant fibrosis in patients 
with viral hepatitis (A1)
• TE is the most accurate non-invasive method for 
detecting cirrhosis in patients with viral hepatitis (A1)Algorithms combining different tests (LS and/or serum biomarkers)
Since the ﬁrst proposal of a strategy combining TE and
FibroTest to increase diagnostic accuracy in patients with hep-
atitis C [126], many algorithms combining either TE and serum
biomarkers [125,143,198–200,202,204,205] or several serum
biomarkers [122,206–210] have been proposed, mainly in
patients with viral hepatitis. Although these algorithms are
more effective in detecting signiﬁcant ﬁbrosis than individual
tests, they do not increase diagnostic accuracy for cirrhosis
[125,196,199]. However, given the important clinical implica-
tions, in terms of prognosis, monitoring and treatment decisions
that follow the diagnosis of cirrhosis, it seems justiﬁed to con-
ﬁrm a diagnosis of cirrhosis by two concordant but unrelated
tests. Also ultrasound and other imaging methods hold a high
speciﬁcity for the diagnosis of cirrhosis in this context, and
may be useful as an unrelated method.
The advantage of combining two unrelated methods, such
as TE and serum biomarkers, over the combination of two
serum biomarkers is that TE provides more direct measure-
ment of the liver structure than biomarkers, and that there
is no relationship between the applicability of TE (success
rate and interquartile range) and that of a biomarker
[204,211]. Also, the combination of TE and serum biomark-
ers might be more effective than the combination of two
serum biomarkers for detecting signiﬁcant ﬁbrosis (signiﬁ-
cantly greater number of saved liver biopsies) [200,212].
However, this strategy has only been validated in studies
of patients with hepatitis C, is more costly, and could be
hampered by the lower applicability of TE, compared with
biomarkers. Most importantly, in case of unexplained discor-
dance of non-invasive tests, a liver biopsy should still be
performed.248 Journal of Hepatology 201Recommendations
• Among the different available strategies, algorithms 
combining TE and serum biomarkers appear to be the 
most attractive and validated one (A2)
• In patients with viral hepatitis C, when TE and serum 
biomarkers results are in accordance, the diagnostic 
accuracy is increased for detecting significant 
fibrosis but not for cirrhosis. In cases of unexplained 
discordance, a liver biopsy should be performed if 
the results would change the patient management. 
Such strategy remains to be validated in patients with 
hepatitis B and NAFLD (A1)Indications for non-invasive tests for staging liver disease in viral
hepatitis
HCV including HIV-HCV
In the clinical management of HCV patients including those coin-
fected with HIV, there are several speciﬁc indications where the
clinician can use non-invasive tests to aid in disease manage-
ment. Either alone or in combination these tests allow for rapid
staging of liver disease without the need for liver biopsy. The cur-
rent gold standard for utilization of non-invasive tests to stage
liver disease is to combine a serum biomarker with TE. The key
for accuracy is to have concordance between the tests, which
increases the diagnostic accuracy (Fig. 1). Every patient with
chronic HCV infection should have liver disease staging at least5 vol. 63 j 237–264
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Treatment-naive
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Whatever HBV DNA level  
and
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Exclude other 
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<6 kPa 6-12 kPa >12 kPa
Fig. 2. Proposed algorithm for the use of transient elastography in treatment-naive patients with Hepatitis B.
JOURNAL OF HEPATOLOGYonce by non-invasive tests. Once a diagnosis of cirrhosis has been
established, both AASLD and EASL guidelines recommend that
those patients should be screened for PH and HCC [213,214].
Therefore all HCV patients need to be staged as part of routine
HCV care to exclude cirrhosis. The diagnostic accuracy of TE for
cirrhosis has been conﬁrmed by multiple studies and meta-
analyzes and has proven superior to that reported by serum
biomarkers.
Recommendations
• All HCV patients should be screened to exclude 
cirrhosis by TE if available. Serum biomarkers can be 
used in the absence of TE (A1)
• HCV patients who were diagnosed with cirrhosis based 
on non-invasive diagnosis should undergo screening 
for HCC and PH and do not need confirmatory liver 
biopsy (A1)HBV
In chronic hepatitis B, TE generally has a higher AUROC as com-
pared to serum biomarkers for advanced liver ﬁbrosisJournal of Hepatology 201[198,202]. Among inactive carriers with normal transaminases,
TE also has less ﬂuctuation over time as compared to
FibroTest or APRI score [155]. LS of <5–6 kPa often indicates
absent or minimal liver ﬁbrosis [132,153]. On the other hand,
LS of >12–14 kPa often indicates liver cirrhosis (Table 5).
Among patients with intermediate LS measurements, the
accuracy of staging is lower. In doubtful cases, liver biopsy is
recommended (Fig. 2). Among chronic hepatitis B patients who
have elevated ALT levels or ALT ﬂares, interpretation of LS mea-
surement should be taken with caution. LS can be misleadingly
high among patients who have severe acute exacerbation of
chronic hepatitis B, even 3–6 months after ALT has been normal-
ized [215].
For HBeAg-positive patients, particularly among those who
are older than 35 years of age with high normal ALT levels,
non-invasive assessment of liver ﬁbrosis is useful to differentiate
whether patients are in immune tolerance phase or already have
signiﬁcant liver ﬁbrosis secondary to immune clearance [216].
In HBeAg-negative patients, the low replicative phase is indi-
cated by normal ALT level and low HBV DNA (<2000 IU/ml). On
the other hand, the reactivation phase is characterized by ele-
vated HBV DNA levels with intermittent elevation of ALT levels.
Patients who have repeated and prolonged reactivation have
higher risks of developing liver cirrhosis [217]. Non-invasive
assessment of liver ﬁbrosis is preferred over liver biopsy among
HBeAg-negative patients with low (<2000 IU/ml) or borderline
(>2000 to 20,000 IU/ml) HBV DNA and normal ALT levels, as the5 vol. 63 j 237–264 249
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risks of advanced ﬁbrosis and cirrhosis in these patients are usu-
ally below 10% [218].
Recommendations
• TE has better prediction for advanced liver fibrosis and 
cirrhosis than serum biomarkers in chronic hepatitis B 
(B1) 
• TE is best used to determine liver fibrosis in hepatitis B 
patients with active viraemia (HBV DNA >2000 IU/ml) 
but normal ALT (A1) 
• TE can be used to exclude severe fibrosis and cirrhosis 
in inactive carriers (HBeAg-negative, low viral load 
(HBV DNA <2000 IU/ml) and normal ALT). Liver biopsy 
should only be considered in doubtful cases after TE 
(A1)
• LS measurement should be interpreted with caution 
among patients with elevated ALT, and should not be 
used in patients with very high ALT levels (>10 x ULN) 
(A1)Use of non-invasive tests for staging liver disease in NAFLD
NAFLD is a very common condition with reported prevalence of
approximately 20% in different parts of the world [219,220].
Simple steatosis does not increase mortality. Fibrosis is the most
important prognostic factor in NAFLD and is correlated with
liver-related outcomes and mortality [2,221]. Advanced ﬁbrosis,
as determined by non-invasive serum biomarker, has been
shown to predict liver-related complications and mortality
[222,223]. Not all NAFLD patients will develop advanced ﬁbrosis.
Biopsy series suggested a prevalence of advanced ﬁbrosis in 50%
of NAFLD patients [222], but a population-based study in Hong
Kong revealed only 3.7% of the 264 NAFLD patients had advanced
ﬁbrosis [224]. NAFLD patients with metabolic syndrome and
those with type 2 diabetes mellitus, had been shown to be at
increased risk of having liver ﬁbrosis in both Western and
Asian cohorts [220,225]. Fibrosis progression is possible among
patients with simple steatosis or non-alcoholic steatohepatitis;
approximately 25% to 37% of patients will have ﬁbrosis progres-
sion in 3–5 years [226–228] [229]. Histologic inﬂammation and
maybe metabolic factors are associated with higher risk of ﬁbro-
sis progression among patients with simple steatosis or steato-
hepatitis [230].
Among the different serum biomarkers studied in NAFLD, only
NFS and FIB-4 have been externally validated more than once, in
different NAFLD populations and with consistent results [119].
These tests perform best at excluding severe ﬁbrosis-cirrhosis
(with negative predictive values >90%) and could therefore be
used as a ﬁrst line triage to identify patients at low risk of severe
ﬁbrosis. TE has excellent diagnostic accuracy for cirrhosis with a
higher rate of false positive results than of false negative results
and higher negative than positive predictive values. Therefore
its ability to rule in severe ﬁbrosis-cirrhosis may be insufﬁcient
for clinical decision making and may require histological
conﬁrmation.250 Journal of Hepatology 201Recommendations
• Screening of liver fibrosis for NAFLD patients is 
recommended, particularly among patients with 
metabolic syndrome or type 2 diabetes mellitus who 
have higher risk of liver fibrosis (A1)
• Non-invasive assessment including serum biomarkers 
or TE can be used as first line procedure for the 
identification of patients at low risk of severe fibrosis/
cirrhosis (A1)
• The identification of significant fibrosis is less accurate 
with non-invasive tests as compared to liver biopsy 
and may necessitate, according to the clinical context, 
histological confirmation (A1)
• Follow-up assessment by either serum biomarkers or 
TE for progression of liver fibrosis should be performed 
among NAFLD patients at a 3 year interval (B1)Use of non-invasive tests for staging liver disease in other liver
diseases
Alcoholic liver disease
Although the use of non-invasive tests in ALD has been explored,
the methodological quality of existing studies is considerably
heterogeneous without evaluation in large cohorts of ALD
patients. Existing information on the usefulness of serum
biomarkers has been recently summarized in the EASL guidelines
for ALD and in recent reviews [231–233]. While a good perfor-
mance has been reported for the use of FibroTest in detecting
signiﬁcant ﬁbrosis and cirrhosis (AUROC = 0.84 for F2-F4,
AUROC = 0.95 for the diagnosis of cirrhosis), APRI has been found
of limited use in the setting of ALD. Of note, FibroMeter and
HepaScore have shown similar diagnostic accuracies than
FibroTest [234] with AUROC around 0.80 for signiﬁcant ﬁbrosis
and 0.90 for cirrhosis. In addition, ELF has also been shown to be
useful in assessing ﬁbrosis in ALD [34]. Interestingly, available
data suggest that serum biomarkers of ﬁbrosis may also be able
to predict clinical outcomes [234,235].
Information on elasticity-based techniques, mainly TE, in ALD
is limited due to the scarcity of single-etiology studies. A recent
systematic review from the Cochrane Collaboration, based on ﬁve
retrospective and nine prospective cohort studies with a total of
834 patients, suggests that TE may be used as a diagnostic
method to rule out severe ﬁbrosis or cirrhosis in patients with
ALD using cut-offs of 9.5 and 12.5 kPa, respectively [236].
However, the authors point out the risk of outcome reporting bias
as well as caution on the use of currently recommended cut-offs
as they are insufﬁciently validated and because there is the risk of
overestimation of LS values in patients that are not abstinent
from alcohol consumption.
Cholestatic liver disease
Available information regarding the use of non-invasive tests in
cholestatic diseases is indeed more limited than that for viral
hepatitis and NAFLD. This is due to the fact that patients with
these diseases are usually part of cohorts of chronic liver disease
and disease speciﬁc data on non-invasive tests performance is5 vol. 63 j 237–264
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not reported separately. In the case of PBC, although histological
proof of the disease is no longer considered mandatory to make
the diagnosis, assessment of the disease stage remains useful
for both prognostic (patients with more advanced disease have
reduced survival than those in earlier stage) and therapeutic rea-
sons (patients with earlier histological stage respond more favor-
ably to UDCA administration and in patients with advanced
disease surveillance of HCC is indicated) [237]. Thus, PBC patients
often undergo a liver biopsy and the use of non-invasive tests of
liver ﬁbrosis may be advantageous in this setting. Several reports
have tested the usefulness of serum biomarkers of liver ﬁbrosis
including serum levels of hyaluronic acid, procollagen III amino-
terminal propeptide, collagen IV, and FibroTest in patients with
PBC [238–240]. While earlier studies did not provide estimates of
diagnostic accuracy to readily assess clinical performance more
recent reports do provide AUC values of ROC curves which in
most of the cases are below 0.8. Thus, current evidence allows
the conclusion that no single serum measurement has the ability
to differentiate between early and advanced ﬁbrosis in PBC [241].
In the case of PSC, no speciﬁc studies are available in this regard.
Reported data on the use of TE in PBC is encouraging. The
report by Corpechot et al. of two cohorts of PBC patients evalu-
ated with TE showed that this technique is currently one of the
best surrogate markers of liver ﬁbrosis in this disease [164].
This data is in agreement with ﬁndings from Floreani’s group in
Italy [242] and with an earlier study by Gomez-Dominguez from
Spain [243]. In addition, TE may be useful to monitor PBC pro-
gression. In fact, prospective data from Corpechot et al. showed
that progression of LS over time is predictive of poor outcome
[164]. As for PSC, a recent study from the same group [244]
showed that TE efﬁciently differentiates severe from non-severe
liver ﬁbrosis stages in this disease, and that both baseline LS mea-
surements and increase over the time are able to predict patients’
outcomes. Thus, TE seems to be a reliable non-invasive method
for assessing biliary ﬁbrosis in PSC patients [163,244]. However,
untreated dominant stricture of the common bile duct or primary
hepatic ducts should be ruled out in PSC patients since obstruc-
tive cholestasis inﬂuences LS assessment [72]. Finally, with the
availability of smaller probes (S1, S2), the use of TE has recently
been tested in children with biliary atresia, a disease where ﬁbro-
sis monitoring may help predict outcomes before surgery [245].
However, more data on non-invasive ﬁbrosis evaluation in
patients with cholestatic liver diseases is needed to make ﬁrm
recommendations on the use of TE in this disease.
Autoimmune hepatitis
AIH may have insidious onset in a signiﬁcant proportion of the
cases, which result in a large number of cases (30% to 80%)
being at the cirrhotic stage at the moment of diagnosis. Since
a signiﬁcant number of cases could be diagnosed without per-
forming a liver biopsy [246], non-invasive tests for liver ﬁbrosis
may have a role in liver disease staging. Non-invasive tests
could be also useful for monitoring response to immunosup-
pressive treatment in AIH, since ﬁbrosis and cirrhosis can be
reversible in this setting [247,248]. However, speciﬁc data of
either serum markers of ﬁbrosis or imaging techniques is scarce
to make recommendations. Of note, disproportionally high
results of TE [249] have been reported in patients with AIH,
which is likely related to the inﬂammatory activity considering
that values decreased rapidly upon induction of disease
remission.Journal of Hepatology 201Recommendations
• TE may be used to rule out severe fibrosis or cirrhosis 
in patients with ALD (B2) 
• Non-invasive assessment of fibrosis, using TE should 
be considered in patients with PBC or PSC (B2) 
• Follow-up assessment of liver fibrosis with TE should 
be performed in PBC and PSC since worsening of 
LS predicts patients’ outcomes. More data is needed 
to define the optimal time-frame between repeated 
examination (B2) 
• Untreated dominant stricture of the common bile duct 
or primary hepatic ducts must be ruled out in PSC 
patients since obstructive cholestasis influences LS 
assessment (A1) 
• No recommendation can be made with current 
evidence on the use of non-invasive tests in AIH (A1) Use of non-invasive methods when deciding for treatment in viral
hepatitis
HCV including HIV-HCV
The current recommendations for treatment of HCV vary signiﬁ-
cantly between countries and healthcare systems according to
the availability of therapy. However, the EASL and AASLD guide-
lines are clear as to the prioritization of treatment based on dis-
ease stage [213,214]. There is some controversy in how best to
use non-invasive tests in HCV therapeutic decisions. In countries
where antiviral treatment is only indicated in patients with sev-
ere ﬁbrosis or cirrhosis, both TE and serum biomarkers are
effective – either alone, or in combination – to assess liver ﬁbro-
sis. However the controversy is with signiﬁcant ﬁbrosis, where
all staging parameters including non-invasive tests and liver
biopsy have the greatest discordance and risk for inaccuracy.
Since the diagnostic accuracy of non-invasive tests in differ-
entiating between stage F1 and F2 has the most variability, this
represents a challenge for clinicians [17,18]. Although cut-offs
for both TE and serum tests have been suggested for signiﬁcant
ﬁbrosis, they have not been well validated and in a large,
prospective US biopsy controlled study in over 700 HCV
patients, TE, APRI, and FIB-4 all performed less well for signiﬁ-
cant ﬁbrosis [129]. Combination of serum biomarkers with TE
may marginally improve differentiation of F0–F1 from F2–F4
but has never been validated in actually differentiating between
the single stages of F1 from F2.
In HIV-HCV coinfected patients, a priority has been given to
treat all patients since this special population shows a more rapid
disease progression so disease staging is less important for thera-
peutic decisions. However, in some countries anti-HCV treatment
in HIV/HCV coinfected patients follows the same guidelines as for
HCV monoinfection. There may be a reduced diagnostic accuracy
of serum biomarkers for ﬁbrosis in HIV-HCV patients and TE
should be preferred.
There have been suggestions that as therapy becomes sim-
pler and more effective with the advent of new direct-acting
antiviral (DAA) agents and an increased uptake of HCV5 vol. 63 j 237–264 251
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screening, that community based physicians, infectious disease
physicians and internists may treat HCV [250]. In this situation,
the role of non-invasive tests is also very important for
determination of appropriate referral of patients with more
advanced liver disease to specialists for appropriate disease
monitoring [81].
Recommendations
• Non-invasive tests, using either TE or serum 
biomarkers, are adequate for diagnosis of severe 
fibrosis/cirrhosis in HCV and HIV-HCV coinfected 
patients and can be used to prioritize patients for HCV 
therapy based on disease stage (A1)
• For the diagnosis of significant fibrosis a combination 
of tests with concordance may provide the highest 
diagnostic accuracy (A2)
• Non-invasive tests should be utilized prior to therapy by 
treating non-specialists to make sure that patients with 
severe fibrosis/cirrhosis are referred for appropriate 
disease specific specialist evaluation (A1)HBV
Liver cirrhosis is the most important risk factor for liver-related
complications and HCC in chronic hepatitis B. According to all
regional guidelines, patients with liver cirrhosis and signiﬁcant
viraemia (HBV DNA >2000 IU/ml) should receive antiviral treat-
ment regardless of the ALT levels [251–253]. Hence, non-invasive
assessment of liver ﬁbrosis can be considered in all patients in
whom liver cirrhosis is suspected. Among hepatitis B patients
who have elevated ALT but not yet reached two times ULN, liver
ﬁbrosis assessment can assist the decision of antiviral therapy.
Patients who have signiﬁcant liver ﬁbrosis and HBV DNA
>2000 IU/ml should be considered for antiviral therapy even if
their ALT levels are below two times ULN [251,252]. Among
patients who have persistently elevated ALT >2 times ULN and
HBV DNA >2000 IU/ml, all regional guidelines recommend com-
mencement of antiviral therapy and liver ﬁbrosis assessment
may not be necessary.
Recommendations
• Non-invasive assessment of liver fibrosis, using either 
serum biomarkers or TE, should be considered for 
patients with significant viraemia (HBV DNA >2000 IU/
ml) when liver cirrhosis is suspected (A1) 
• Among patients who have HBV DNA >2000 IU/ml, 
antiviral therapy should be considered for patients who 
have advanced fibrosis or cirrhosis as determined by 
non-invasive assessment of liver fibrosis, either by 
serum biomarkers or TE, regardless of the ALT levels 
(A1) 252 Journal of Hepatology 201Use of non-invasive methods for monitoring treatment response in
viral hepatitis
HCV including HIV-HCV
A major advantage of non-invasive tests, compared with liver
biopsy, is that they can be easily repeated over time in patients
receiving antiviral therapy and that they could be used to moni-
tor response to treatment and to evaluate ﬁbrosis regression.
Several studies reported a signiﬁcant decrease in LS and
biomarkers values, compared with baseline values, in patients
with HCV who achieved SVR [254–263], consistent with signiﬁ-
cant histologic improvement documented in studies of paired
liver biopsies from HCV patients who achieved SVR [264,265].
However, the changing levels of ALT and inﬂammation of suc-
cessfully treated HCV patients can confound results of TE or bio-
markers. Indeed, the major component of the signiﬁcant
decrease observed in LS and biomarkers values is not just rever-
sal of ﬁbrosis but also reduction in liver injury, edema and
inﬂammation.
There are two important clinical questions about the use of
non-invasive tests after antiviral treatment. First, what is the evi-
dence of ﬁbrosis and particularly cirrhosis reversal by non-inva-
sive tests? The reversal of cirrhosis has important consequences
in that it may alter long-term prognosis particularly for HCC
occurrence in HCV patients and change the approach to screening
and surveillance for HCC after SVR. This leads into the second
question, what are the cut-off thresholds post SVR for determina-
tion of decreased risk of liver-related outcomes?
In HCV, there is only one study that has examined reversal of
cirrhosis in 33 patients with cirrhosis with pre- and post-treat-
ment liver biopsies and TE after SVR [266]. There was reversal
of cirrhosis by biopsy in 19 patients with 11 of the 19 being
METAVIR F3 and the remainder F1 or F2. Using a cut-off of
12 kPa, TE had a sensitivity of 61% and a speciﬁcity of 95%. The
low sensitivity makes TE a poor tool to be utilized clinically as
evidence of cirrhosis regression. Non-invasive tests, including
TE and serum biomarkers, have been shown to predict liver-re-
lated outcomes in HCV patients [267,268]. In both these studies
clinical cut-offs of LS between 9.5 and 10.5 kPa were able to strat-
ify patients at increased risk of clinical liver-related outcome. The
best timing for repeated assessment of LS after therapy has not
been established yet.
Recommendations
• Routine use of non-invasive tests during treatment 
or after SVR in non-cirrhotic patients does not add to 
clinical disease management (A1)
• Routine use of non-invasive tests after SVR in patients 
with HCV cirrhosis has a high false negative rate and 
cannot be used to determine which patients no longer 
need HCC screening or for the diagnosis of cirrhosis 
reversal (A2)
• Routine use of non-invasive tests after SVR has not 
yet established thresholds that predict low risk of liver-
related events (A1)5 vol. 63 j 237–264
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HBV
Prolonged treatment with antiviral therapy is associated with
resolution of liver ﬁbrosis and regression of liver cirrhosis
[269–271]. Non-invasive tests are an attractive strategy to moni-
tor changes in ﬁbrosis. A signiﬁcant decrease in LS and biomark-
ers values, compared with baseline values, in HBV-infected
patients treated with analogs has been reported [272–281].
However, like for HCV patients, improvement of LS in HBV
patients who start antiviral therapy when ALT is elevated may
be related to normalization of ALT instead of ﬁbrosis improve-
ment [274]. In this case, a LS measurement a few months after
commencing treatment and normalization of ALT is recom-
mended as baseline to monitor the changes in liver ﬁbrosis. The
value of non-invasive tests to predict the occurrence of com-
plications or survival in patients with undetectable HBV DNA
and cirrhosis prior to antiviral treatment remains to be deter-
mined [282–284].Table 8. Prognostic performance of TE for predicting development of HCC in patien
Authors Etiologies Year Total patients 
(n)
HCC 
patients (n)
Masuzaki et al. 
[312]
HCV 2008 265 85
Nahon et al. [313]^ Mixed 2009 265 66
Kuo et al. [311] Mixed 2010 435 106
Feier et al. [310] HCV 2013 144 72
Masuzaki et al. 
[317]
HCV 2009 866 77
Akima et al. [314] HCV* 2011 157 41 (10)**
Wang et al. [319] HCV 2013 198 10
Narita et al. [318] HCV 2013 151 9
Jung et al. [316] HBV 2011 1130 57
Chon et al. [315] HBV 2012 1126 63
Fung et al. [275] HBV 2011 528 7
Kim et al. [321] HBV 2012 128 13
Kim Do et al. [320] HBV¥ 2013 162 12
Robic et al. [322] Mixed 2011 100 4
Klibansky et al. 
[267]
Mixed 2012 667 16
Poynard et al. [323] HCV 2014 3927 84
^Liver cirrhosis with Child-Pugh class A. ⁄Mostly HCV with 85.4%. ⁄⁄41 patients with HC
All patients treated with interferon; All patients were HBeAg-negative; ¥All patients c
TE, transient elastography; HCC, hepatocellular carcinoma; AUROC, area under the rece
hepatitis B virus; n.a., not available.
Journal of Hepatology 201Recommendations
• Non-invasive assessment with either serum biomarkers 
or TE can be used to monitor improvement in liver 
fibrosis during antiviral therapy. The correlation of 
fibrosis improvement predicted by non-invasive 
measurement with histology has yet to be determined 
(B2)
• The impact of ALT normalization by antiviral therapy 
has to be considered on interpretation of the non-
invasive liver fibrosis assessment results (A1) ts with chronic liver disease.
Region Design Follow-up 
duration 
(months)
AUROC Cut off 
value 
(kPa)
Asia Cross-
sectional
- 0.805 25
Europe Cross-
sectional
- n.a. n.a.
Asia Cross-
sectional
- 0.736 24
Europe Cross-
sectional
- 0.680 38.5
Asia Longitudinal 
prospective
36.0 n.a. 25
Asia Longitudinal 
prospective
40.7 0.787 12.5
Asia Longitudinal 
prospective
47.8 n.a. 12
Asia Longitudinal 
prospective
24.1 n.a. 14
Asia Longitudinal 
prospective
30.7 n.a. 8
Asia Longitudinal 
prospective
30.7 0.789 n.a.
Asia Longitudinal 
prospective
35.0 n.a. 10
Asia Longitudinal 
prospective
27.8 0.722 19
Asia Longitudinal 
prospective
 24.0 0.736 12
Europe Longitudinal 
prospective
24.0 0.837 21.1
USA Longitudinal 
prospective
28.7 0.870 10.5
Europe Longitudinal 
prospective
144 0.860 50
C at the time of enrollment, 10 patients developed HCC during follow-up.
ompleted 2-year entecavir treatment.
iver operating characteristic curve; kPa, kilopascal; HCV, hepatitis C virus; HBV,
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Use of non-invasive tests for monitoring disease progression
Portal hypertension
There is substantial evidence indicating that TE can be quite effec-
tive in detecting patients with a high risk of having (or not having)
developed clinically signiﬁcant elevations of hepatic venous pres-
sure gradient (HVPG) or varices. Several studies have shown that
there is a good correlation between LS values and HVPG in
patients with advanced liver diseases in both pre- and post-trans-
plant settings [285–288]. According to a recent meta-analysis, the
diagnostic performance of TE for predicting clinically signiﬁcant
PH (CSPH, HVPGP10 mmHg) in the setting of patients with com-
pensated chronic liver disease/cirrhosis is excellent, with an
AUROC of 0.93 [289]; a 90% sensitive cut-off for CSPH diagnosis
is 13.6 kPa, and a 90% speciﬁc cut-off in this setting is 21 kPa.
These cut-offs have been shown to allow a correct stratiﬁcation
of presence/absence of CSPH in patients with compensated cirrho-
sis and potentially resectable HCC, thus reducing the need for
invasive hemodynamic assessment [290]. However, while the
correlation is excellent for HVPG values between 5 and 10–
12 mmHg (typical of cirrhosis without evident clinical mani-
festations related to PH), it hardly reaches statistical signiﬁcance
for values above 12 mmHg [286]. This is because, with the pro-
gression of cirrhosis, the mechanisms of PH become less and less
dependent on the intrahepatic resistance to portal ﬂow due to tis-
sue ﬁbrosis and progressively more dependent on extra-hepatic
factors (i.e. hyperdynamic circulation, splanchnic vasodilatation)
[291]. This observation sets a key limitation to the use of LS mea-
surements as a non-invasive surrogate of HVPG beyond the pre-
diction of clinically signiﬁcant (HVPG P10 mmHg) and severe
(HVPG P12 mmHg) PH, and, accordingly, TE of the liver is unli-
kely to be useful in monitoring the hemodynamic response to
the administration of beta-blockers or disease progression in the
decompensated phase. Conversely, repeated LS measurements
could be useful during the ﬁrst year after liver transplantation
to identify patients with hepatitis C recurrence characterized by
a rapid progression towards cirrhosis [292]; in addition, a LS
P8.7 kPa one year after orthotopic liver transplantation is associ-
ated to a worse prognosis in this setting [293].
More uncertain and controversial is the possibility of predict-
ing the presence and the size of oesophageal varices (OV) based
on LS values. A correlation between LS values and the presence
of OV has been reported in several studies [196,286–288,294–296]
with AUROCs ranging from 0.74 to 0.85 and cut-offs from 13.9
to 21.5 kPa. Although the sensitivity for the prediction of the
presence of OV was high (76–95%), speciﬁcity was in general
not satisfactory (43–78%). Regardless, the general features of
these studies, i.e. single-centre retrospective, heterogeneous
etiology of cirrhosis and stages of disease progression, subjective
assessment of OV size, do not allow any sound conclusion on the
utility of LS assessment in predicting the presence of OV and to
screen cirrhotic patients without endoscopy [297].
Recently, studies employing different technical approaches
have highlighted the potential utility of spleen stiffness (SS)
assessment for predicting the presence of OV and the degree of
PH in cirrhotic patients [298–302]. In particular, the study by
Colecchia and co-workers [300] measured SS and LS by TE in
100 consecutive patients with HCV–induced cirrhosis. All
patients also underwent measurements of HVPG and upper GI
endoscopy. The ability of both SS and LS to predict clinically sig-
niﬁcant PH and the presence of OV was compared to that of the254 Journal of Hepatology 201previously proposed methods, i.e. the LS–spleen diameter to pla-
telet ratio score (LSPS) and platelet count to spleen diameter
[303–305]. SS and LS were more accurate than other non-invasive
parameters in identifying patients with OV and different degrees
of PH. Further validation is needed before the place of SS in clini-
cal practice can be deﬁned.
Several biological parameters have been proposed for the
non-invasive detection of CSPH including prothrombin time
[287], a score combining platelet count and total bilirubin
[306], and FibroTest [307]. In particular, a score combining pla-
telet count with total bilirubin had an AUROC of 0.91 for predict-
ing CSPH with 88% sensitivity and 86% speciﬁcity at a cut-off of
1.0.
Similarly, several non-invasive tools have been proposed for
the detection of OV including routine biological parameters
[308], FibroTest [309], and combination of simple biological
and ultrasound parameters [303]. In the largest study to date
comparing retrospectively a panel of serum markers (platelet
count, AST/ALT ratio, APRI, Forns index, Lok index, FIB-4, and
Fibroindex) in more than 500 patients with chronic liver diseases,
the combination of Lok index (cut-off = 1.5) and Forns index (cut-
off = 8.8) had the best diagnostic performance (AUROC of 0.80
and negative predictive value of 90%) for predicting clinically
relevant OV [308].
In conclusion, the evidence accumulated so far indicates that
both HVPG and upper GI endoscopy cannot be replaced by non-
invasive methods, although an initial non-invasive approach
may be helpful in selecting patients in whom these procedures
are indicated with a certain level of urgency.
Hepatocellular carcinoma
To date, several cross-sectional studies [310–313] identiﬁed that
high LS value measured by TE is signiﬁcantly associated with
the risk of presence of HCC (Table 8). However, these cross-sec-
tional studies only describe the ‘static’ phenomenon that
patients with HCC have high LS values than those without
HCC, not considering the ‘dynamic’ association between the pro-
gression or regression of liver ﬁbrosis and the risk of future HCC
development. To overcome this limitation, several longitudinal
prospective studies [267,314–323] have recently been published
(Table 8).
A large prospective cohort study with chronic hepatitis C (866
patients) was conducted in Japan [317]. Along with age, male
gender, and clinical cirrhosis, stratiﬁed LS values were identiﬁed
as an independent risk factor for HCC development. Compared
with patients with LS values 610 kPa, patients with higher LS val-
ues were at signiﬁcantly increased risk of developing HCC (LS val-
ues, 10.1–15 kPa, hazard ratio [HR], 16.7; LS values, 15.1–20 kPa,
HR, 20.9; LS values, 20.1–25 kPa, HR, 25.6; and LS values, >25 kPa,
HR, 45.5). In addition, the cumulative incidence rates of HCC
showed a stepwise increase according to the stratiﬁed LS values
(p <0.001 by the log-rank test). In addition, Jung et al. [316] fur-
ther validated the usefulness of TE in prediction of HCC develop-
ment in patients with chronic hepatitis B (n = 1130). Compared
with patients with LS values 68 kPa, patients with higher LS val-
ues were at signiﬁcantly increased risk of developing HCC (LS val-
ues, 8.1–13 kPa, HR, 3.07; LS values, 13.1–18 kPa, HR, 4.68; LS
values, 18.1–23 kPa, HR, 5.55; and LS values, >23 kPa, HR, 6.60).
Furthermore, changes in the risk of HCC development according
to the pattern of changes in the measured LS was also shown in
the study, suggesting a potential role for serial LS measurement5 vol. 63 j 237–264
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as a dynamic monitoring tool for risk estimation of HCC
development in patients with chronic hepatitis B. All these results
implied that TE is useful in estimating the risk of HCC development
in patients with chronic liver disease across the etiology despite
different carcinogenetic mechanisms of HCV and HBV.
Based on the close relationship between TE and the risk of
HCC development, several studies have tried to develop and vali-
date LS-based prediction models for HCC development
[310,320,324]. Wong et al. [324] evaluated the accuracy of LS-
HCC score, reﬁned from their previous CU-HCC score [325] in
1555 Asian patients with chronic hepatitis B. The AUROC of LS-
HCC score was higher than that of CU-HCC score in predicting
HCC development (0.83 vs. 0.75 at 3 year, 0.89 vs. 0.81 at 5 year).
More recently, Kim et al. [320] also introduced a predictive model
based on a Cox proportional hazards model using age, male gen-
der, LS value, and HBV DNA in patients with chronic hepatitis B.
This model showed good discrimination capability, with an
AUROC of 0.806 (95% CI 0.738–0.874) and AUROC remained lar-
gely unchanged between iterations, with an average value of
0.802 (95% CI 0.791–0.812). The predicted risk of HCC occurrence
calibrated well with the observed risk, with a correlation coefﬁ-
cient of 0.905 (p <0.001).
According to all the results regarding non-invasive markers, it
can be concluded that non-invasive methods are not merely an
alternative to biopsy for staging ﬁbrosis, but also predictive of
the incidence of liver-related complications of liver ﬁbrosis,
including HCC development. However, further studies focusing
on diverse etiologies of chronic liver disease, such as ALD or
NAFLD, are needed to expand the clinical prognostic usefulness
of non-invasive methods. In addition, optimal cut-off values with
respect to the different etiologies of chronic liver disease to assess
the risk of HCC development should be set up in subsequent lar-
ger longitudinal prospective studies. In spite of several lim-
itations, non-invasive methods to assess and monitor the risk of
HCC development will help physicians to establish optimum
treatment strategies. It should be further investigated whether
the accuracy of the surveillance strategy can be enhanced, if these
non-invasive methods are incorporated into the routine surveil-
lance strategy.
Recommendations
• Non-invasive tests cannot replace HVPG for a detailed 
PH evaluation and upper GI endoscopy for detecting 
varices (A1)
• However, in settings where HVPG is not available, TE 
could be considered to stratify the risk of CSPH (A2)
• Although TE could be useful to identify patients at risk 
of developing HCC, more data are needed before it 
can be integrated into an HCC surveillance program 
(A1)
Determining prognosisThere is increasing evidence for the prognostic value of non-inva-
sive tests in patients with chronic liver diseases. Several recentJournal of Hepatology 201studies have shown that in patients with chronic liver disease,
LS could also predict clinical decompensation as well as survival
[244,268,282,321,322,326,327,328]. For instance, Robic et al.
[322] found that TE was as effective as HVPG in predicting clinical
decompensations in 100 patients with chronic liver disease with
a 2 year follow-up. Both HVPGP10 mmHg and LSP21.1 kPa had
100% NPV for portal-hypertensive complications. Similarly, in a
cohort of 128 Korean patients with active HBV cirrhosis, LS at a
cut-off of 19 kPa, had a hazard ratio of 7 for development of clini-
cal decompensation [321]. In a cohort of 1457 HCV patients, LS
values and FibroTest had the highest 5 year predictive values
for predicting survival and liver-related death, which did not
change after adjustment for treatment response, patient age,
and estimates of necro-inﬂammatory grade [268]. Interestingly,
Corpechot et al. [244] have shown in 168 patients with PSC that,
not only those with high baseline but also those with increase in
LS values (>1.5 kPa/year) were at a very high risk (approximately
10 times the risk estimated in the other group) of death, liver
transplantation, or hepatic complications within a 4 year period.
In another study in 1025 patients with chronic hepatitis C, the
prognosis of patients with LS between 7 and 14 kPa on inclusion
was signiﬁcantly impaired when an increase P1 kPa/year was
observed [263].
Finally, it has been recently suggested that SS could predict
the occurrence of complications [329]. Thus the potential of LS
values for predicting clinical outcomes seems to be greater than
that of liver biopsy, probably LS measures ongoing pathophysio-
logical processes and functions that a biopsy cannot.
Similarly, serum biomarkers such as FibroTest [154,234,330],
ELF [235,239], APRI and FIB-4 [222,331], as well as for models
based on standard laboratory tests [332,333] have been shown
to have prognostic value in various chronic liver diseases.
Recommendations
• There is increasing evidence for the prognostic value of 
non-invasive tests, particularly LS measurement using 
TE, in patients with cirrhosis (A1)
• Increase of LS values over time could be associated 
with a worse prognosis in patients with fibrosis or 
cirrhosis (A2)
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